[go: up one dir, main page]

EE04000B1 - Farmatseutiline preparaat prostata hüpertroofia ja prostatakartsinoomi raviks - Google Patents

Farmatseutiline preparaat prostata hüpertroofia ja prostatakartsinoomi raviks

Info

Publication number
EE04000B1
EE04000B1 EEP199900121A EE9900121A EE04000B1 EE 04000 B1 EE04000 B1 EE 04000B1 EE P199900121 A EEP199900121 A EE P199900121A EE 9900121 A EE9900121 A EE 9900121A EE 04000 B1 EE04000 B1 EE 04000B1
Authority
EE
Estonia
Prior art keywords
prostate
treatment
pharmaceutical preparation
hypertrophy
carcinoma
Prior art date
Application number
EEP199900121A
Other languages
English (en)
Estonian (et)
Other versions
EE9900121A (et
Inventor
Engel J�rgen
Reissmann Thomas
Riethm�ller-Winzen Hilde
Rawert J�rgen
Original Assignee
Asta Medica Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica Aktiengesellschaft filed Critical Asta Medica Aktiengesellschaft
Publication of EE9900121A publication Critical patent/EE9900121A/xx
Publication of EE04000B1 publication Critical patent/EE04000B1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/09Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EEP199900121A 1996-09-12 1997-09-01 Farmatseutiline preparaat prostata hüpertroofia ja prostatakartsinoomi raviks EE04000B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2599096P 1996-09-12 1996-09-12
US4322897P 1997-04-10 1997-04-10
PCT/EP1997/004740 WO1998010781A1 (en) 1996-09-12 1997-09-01 Means for treating prostate hypertrophy and prostate cancer

Publications (2)

Publication Number Publication Date
EE9900121A EE9900121A (et) 1999-10-15
EE04000B1 true EE04000B1 (et) 2003-04-15

Family

ID=26700570

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP199900121A EE04000B1 (et) 1996-09-12 1997-09-01 Farmatseutiline preparaat prostata hüpertroofia ja prostatakartsinoomi raviks

Country Status (28)

Country Link
US (4) US6054432A (is)
EP (1) EP0925069B1 (is)
JP (1) JP2001500500A (is)
KR (1) KR100546235B1 (is)
CN (1) CN1126566C (is)
AR (1) AR009757A1 (is)
AT (1) ATE370743T1 (is)
AU (1) AU738306B2 (is)
BR (1) BR9713197A (is)
CA (1) CA2215015A1 (is)
CZ (1) CZ298738B6 (is)
DE (1) DE69738045T2 (is)
DK (1) DK0925069T3 (is)
EE (1) EE04000B1 (is)
ES (1) ES2289764T3 (is)
HU (1) HUP0000261A3 (is)
IL (3) IL128331A0 (is)
IS (1) IS4978A (is)
MX (1) MXPA99002420A (is)
NO (1) NO326207B1 (is)
NZ (1) NZ334540A (is)
PL (1) PL193184B1 (is)
PT (1) PT925069E (is)
RU (1) RU2215537C2 (is)
SK (1) SK286174B6 (is)
TR (1) TR199900556T2 (is)
TW (1) TWI224002B (is)
WO (1) WO1998010781A1 (is)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
US6054432A (en) * 1996-09-12 2000-04-25 Asta Medica Aktiengesellschaft Means for treating prostate hypertrophy and prostate cancer
FR2768055A1 (fr) * 1997-09-11 1999-03-12 Synthelabo Utilisation de derives de sulfonanilide pour obtenir un medicament destine au traitement de l'ejaculation retrograde ou de l'aspermie
TW536402B (en) * 1998-06-26 2003-06-11 Yamanouchi Pharma Co Ltd Pharmaceutical composition for the therapy of voiding dysfunction
DE19911771B4 (de) * 1999-03-17 2006-03-30 Zentaris Gmbh LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung
US6545034B1 (en) * 1999-07-23 2003-04-08 The Regents Of The University Of California Use of etodolac for the treatment of chronic lymphocytic leukemia
US7129262B2 (en) * 1999-07-23 2006-10-31 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
US7105560B1 (en) 1999-07-23 2006-09-12 The Regents Of The University Of California Use of etodolac in the treatment of multiple myeloma
US7151100B1 (en) * 1999-07-23 2006-12-19 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
US7361680B2 (en) * 1999-07-23 2008-04-22 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
ID30249A (id) * 1999-08-09 2001-11-15 Yamanouchi Pharma Co Ltd Komposisi farmasi untuk terapi gejala-gejala penyakit pelaksanaan fungsi saluran air kencing bawah
CA2669753C (en) 1999-09-30 2012-06-26 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment of androgen receptor driven conditions
US20040152672A1 (en) * 2000-08-09 2004-08-05 Carson Dennis A. Indole compounds useful for the treatment of cancer
DE10040700A1 (de) * 2000-08-17 2002-02-28 Asta Medica Ag Salze von biologisch aktiven Peptiden, ihre Herstellung und Verwendung
KR100876538B1 (ko) * 2000-08-17 2008-12-31 아에테르나 젠타리스 게엠베하 Lhrh 길항제의 염의 제조방법
JP2001288115A (ja) * 2001-02-07 2001-10-16 Yamanouchi Pharmaceut Co Ltd 下部尿路症治療剤
DE10137174A1 (de) * 2001-07-31 2003-02-13 Zentaris Ag Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität
US7211599B2 (en) * 2002-09-19 2007-05-01 The Regents Of The University Of California Use of etodolac to treat hyperplasia
GB0301016D0 (en) * 2003-01-16 2003-02-19 Univ London Treatment of benign prostatic hyperplasia
MXPA05007572A (es) 2003-01-17 2005-11-17 Threshold Pharmaceuticals Inc Tratamiento de hiperplasia prostatica benigna.
CN101677975B (zh) * 2006-05-03 2013-06-26 威斯康星校友研究基金会 N1,n4-双(丁-1,3-二烯基)丁-1,4-二胺药物组合物及其方法
EP1891964A1 (en) * 2006-08-08 2008-02-27 AEterna Zentaris GmbH Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits
EP1967202A1 (en) * 2007-03-05 2008-09-10 AEterna Zentaris GmbH Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity
EP2095818A1 (en) * 2008-02-29 2009-09-02 AEterna Zentaris GmbH Use of LHRH antagonists at non-castrating doses
US10585101B2 (en) 2016-03-10 2020-03-10 Wavesense, Inc. Prostatic liquid biopsy for the detection of prostate cancer and benign prostatic hyperplasia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2465486A1 (fr) * 1979-09-21 1981-03-27 Roussel Uclaf Nouvelle application utilisant la lh-rh ou des agonistes
HU199694B (en) * 1988-05-10 1990-03-28 Innofinance Altalanos Innovaci Process for producing citostatic pharmaceutical compositions containing gonadoliberin derivatives
DE3918543A1 (de) * 1989-06-07 1990-12-13 Boehringer Mannheim Gmbh Verwendung von naftopidil zur therapie der dysurie bei benigner prostata-hypertrophie
IL101245A0 (en) * 1991-03-20 1992-11-15 Merck & Co Inc Pharmaceutical compositions for the treatment of prostatic cancer
IL101243A (en) * 1991-03-20 1999-12-22 Merck & Co Inc Pharmaceutical preparations for the treatment of benign prostatic hyperplasia containing steroid history
US6054432A (en) * 1996-09-12 2000-04-25 Asta Medica Aktiengesellschaft Means for treating prostate hypertrophy and prostate cancer

Also Published As

Publication number Publication date
EP0925069B1 (en) 2007-08-22
IL128331A0 (en) 2000-01-31
PL332085A1 (en) 1999-08-30
CA2215015A1 (en) 1998-03-12
IS4978A (is) 1999-02-16
HK1021937A1 (en) 2000-07-21
US6071882A (en) 2000-06-06
HUP0000261A2 (hu) 2000-10-28
CN1230121A (zh) 1999-09-29
MXPA99002420A (es) 2004-08-27
NO991192D0 (no) 1999-03-11
DE69738045D1 (de) 2007-10-04
DE69738045T2 (de) 2008-05-15
CN1126566C (zh) 2003-11-05
US6054432A (en) 2000-04-25
HUP0000261A3 (en) 2001-03-28
WO1998010781A1 (en) 1998-03-19
NZ334540A (en) 2000-07-28
PT925069E (pt) 2007-10-17
ATE370743T1 (de) 2007-09-15
ES2289764T3 (es) 2008-02-01
TWI224002B (en) 2004-11-21
AU4619897A (en) 1998-04-02
AU738306B2 (en) 2001-09-13
IL128331A (en) 2010-05-31
CZ298738B6 (cs) 2008-01-09
EE9900121A (et) 1999-10-15
BR9713197A (pt) 2000-04-04
PL193184B1 (pl) 2007-01-31
RU2215537C2 (ru) 2003-11-10
JP2001500500A (ja) 2001-01-16
NO326207B1 (no) 2008-10-20
US6300313B1 (en) 2001-10-09
EP0925069A1 (en) 1999-06-30
IL189132A0 (en) 2008-06-05
CZ80899A3 (cs) 1999-11-17
DK0925069T3 (da) 2007-10-29
US5998377A (en) 1999-12-07
NO991192L (no) 1999-04-28
TR199900556T2 (xx) 1999-07-21
SK30199A3 (en) 2000-03-13
KR100546235B1 (ko) 2006-01-26
AR009757A1 (es) 2000-05-03
KR20010029495A (ko) 2001-04-06
SK286174B6 (sk) 2008-04-07

Similar Documents

Publication Publication Date Title
EE9900121A (et) Farmatseutiline preparaat prostata hüpertroofia ja prostatakartsinoomi raviks
FI970990A7 (fi) Syövän toteaminen ja hoito
DE69738547D1 (de) Kartierender katheter
DE69732566D1 (de) Selbstausrichtender katheter
FR11C0020I2 (fr) Dérives difluoroprostaglandines et leur application
NO983266D0 (no) Distribuert Behandling
NO984431L (no) FremgangsmÕte for behandling av smerte
EE04390B1 (et) Paikne preparaat dermatoloogiliste seisundite raviks
DE69627513D1 (de) Kochgerät und dessen betriebsverfahren
NO971015L (no) Forbindelser og metoder for behandling av cancer
FI972484L (fi) Karsinooman hoito
NO990918D0 (no) Ringformet kateter
DE69717416D1 (de) Rotationszerstäubungskopf
ID18679A (id) Penggunaan terapi lanjutan
ATE239509T1 (de) Konjugate zur behandlung von prostatakrebs
FI980246A0 (fi) Menetelmä keittimen käyttämiseksi ja keitin
NO993066D0 (no) Ny behandling for leddinflammasjon
DE69524550D1 (de) Entzündungshemmende schmerzstillende anhaftende Zubereitungen
NO983263D0 (no) Distribuert behandling
NO984446D0 (no) FremgangsmÕte for behandling av smerte
PT984777E (pt) Piperazinas arilsubstituidas uteis no tratamento da hiperplasia benigna da prostata
DK0826679T3 (da) Naphthylforbindelser og -præparater
ID19542A (id) Pengobatan baru
EP0965340A4 (en) DERMATOLOGICAL COMPOSITIONS
FI980543A0 (fi) Spetsdragningsanordning och foerfarande foer spetsdragning av en bana

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

HC1A Change of owner name
KB4A Valid patent at the end of a year

Effective date: 20051231

HE1A Change of address
KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20100901